New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
16:07 EDTVRTXVertex submits sNDA to FDA for Kalydeco
Vertex Pharmaceuticals announced the submission of a supplemental New Drug Application, or sNDA, to the FDA for the approval of Kalydeco in people with cystic fibrosis, or CF, ages 18 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. In the United States, Kalydeco is currently approved for use in people with CF ages 6 and older who have one of the following nine mutations: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D. CF is caused by a defective or missing CFTR protein that results from mutations in the CFTR gene. In the United States, approximately 300 people have the R117H mutation and are 18 years of age or older. R117H is the most common residual function mutation and also has a defect in the gating of the CFTR protein.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
07:26 EDTVRTXWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
April 30, 2015
07:59 EDTVRTXVertex price target raised to $150 from $131 at Leerink
Subscribe for More Information
April 29, 2015
17:49 EDTVRTXVertex CEO says Orkambi currently under review by the FDA
Subscribe for More Information
16:04 EDTVRTXVertex sees FY15 Kalydeco revenue $560M-$580M
Sees FY15 combined non-GAAP R&D and SG&A expenses will be in the range of $1.05B-$1.10B.
16:02 EDTVRTXVertex reports Q1 EPS (62c), consensus (75c)
Reports Q1 revenue $138.51M, consensus $142.38M.
15:00 EDTVRTXNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use